Lang A B, Fürer E, Cryz S J
Department of Immunology, Swiss Serum and Vaccine Institute, Bern, Switzerland.
FEMS Immunol Med Microbiol. 1993 Jun;7(1):9-13. doi: 10.1111/j.1574-695X.1993.tb00375.x.
In a murine model of Gram-negative sepsis, we have shown that the prophylactic application of human monoclonal antibodies (HmAbs) with specificity for lipopolysaccharides (LPS) of Pseudomonas aeruginosa protected against bacterial infection. In this paper we show that the therapeutical application of 5 micrograms of these HmAbs up to 6 h after challenge with a lethal dose of live P. aeruginosa results in a protection rate of 70-90%. Administration 18 h after bacterial challenge, diminished the protection to 43% survival rate. Furthermore, using a mixture of HmAbs recognizing a total of six different P. aeruginosa serotypes, no interference in their protective capacities was found. Finally, these HmAbs also protected galactosamine-sensitized mice against lethal challenge with LPS. Our data show that the described HmAbs confer bactericidal activity as well as anti-endotoxic activity in vivo.
在革兰氏阴性脓毒症的小鼠模型中，我们已经表明，预防性应用对铜绿假单胞菌脂多糖（LPS）具有特异性的人单克隆抗体（HmAbs）可预防细菌感染。在本文中，我们表明，在给予致死剂量的活铜绿假单胞菌攻击后6小时内，应用5微克这些HmAbs进行治疗，保护率可达70%-90%。在细菌攻击后18小时给药，保护率降至43%。此外，使用识别总共六种不同铜绿假单胞菌血清型的HmAbs混合物，未发现它们的保护能力受到干扰。最后，这些HmAbs还保护半乳糖胺致敏的小鼠免受LPS致死性攻击。我们的数据表明，所述HmAbs在体内具有杀菌活性以及抗内毒素活性。
